Dihydrothienopyrimidines for the treatment of inflammatory diseases

US8604039B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Pascale Pouzet · Biberach, DE
• Christoph Hoenke · Ingelheim am Rhein, DE
• Rolf Goeggel · Ulm, DE
• Birgit Jung · Laupheim, DE
• Peter Nickolaus · Warthausen, DE
• Dennis Fiegen · Biberach an der Riß, DE
• Thomas Fox · Biberach, DE

Key dates

• Filing date: Jan 4, 2012
• Grant date: Dec 10, 2013
• Expiry date: Jan 4, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof,wherein X is SO or SO2, but preferably SO, and wherein R1, R2 and R3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.